CME / ABIM MOC / CE

Multiple Myeloma

Authors: Session chair: Shaji Kumar, MD; Faculty: Anita D'Souza, MD; Charise Gleason, MSN, NP-C, AOCNP; Nisha Joseph, MD; Amrita Krishnan, MD, FACP; Sagar Lonial, MD, FACP; Kathryn Maples, PharmD, BCOP; Ajay Nooka, MD, MPH, FACP; Krina Patel, MD, MSc
CME / ABIM MOC / CE Released: 10/11/2022
Valid for credit through: 10/11/2023

Credits Available

Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 2.50 ABIM MOC points

Nurses - 2.50 ANCC Contact Hour(s) (2.25 contact hours are in the area of pharmacology)

Pharmacists - 2.50 Knowledge-based ACPE (0.250 CEUs)

IPCE - 2.25 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with hematologic disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), benign hematologic diseases, and other related conditions.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recent clinical trial data on treatment strategies for multiple myeloma
Have greater competence related to
- Selecting evidence-based treatment for patients with newly diagnosed or relapsed/refractory multiple myeloma
- Managing adverse events associated with current therapies for patients with multiple myeloma
Demonstrate greater confidence in their ability to
- Personalize treatment for patients with multiple myeloma in an interprofessional team-based environment

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Session chair

Shaji Kumar, MD

Professor of Medicine
Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, Minnesota

Disclosures

Shaji Kumar, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Amgen; Antengene; ArcellX; AstraZeneca; BeiGene; Bluebird; Bristol Myers Squibb Company; Epizyme; Genentech; Janssen; K36 Therapeutics; Loxo; Monterosa; Oncopeptides; Roche; Sanofi; SecuraBio; Trillium
Research funding from: AbbVie; Amgen; Allogene; AstraZeneca; Bristol Myers Squibb Company; Carsgen; Genentech; GlaxoSmithKline; Janssen; Molecular Templates; Novartis; Regeneron; Roche; Takeda

Faculty

Nisha Joseph, MD

Assistant Professor
Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Joseph and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Joseph’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Nisha Joseph, MD, has no relevant financial relationships.

Ajay Nooka, MD, MPH, FACP

Associate Professor
Department of Hematology and Medical Oncology
Medical Director
Winship Data and Technology Applications Shared Resource
Winship Cancer Institute of Emory University
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Nooka and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Nooka’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Ajay Nooka, MD, MPH, FACP, has the following relevant financial relationships:
Consultant or advisor for: Adaptive; Amgen; Beyond Springs; Bristol Myers Squibb Company; GlaxoSmithKline; Karyopharm; Legend; Oncopeptides; Sanofi; SecuraBio; Takeda
Research funding from: Amgen; Arch; Bristol Myers Squibb Company; Genentech; GlaxoSmithKline; Janssen; Karyopharm; Kite; Takeda

Amrita Krishnan, MD, FACP

Director
Judy and Bernard Briskin Center for Multiple Myeloma Research
Professor
Department of Hematology and Hematopoietic Cell Transplantation
City of Hope Medical Center
Duarte, California

Disclosures

Amrita Krishnan, MD, FACP, has the following relevant financial relationships:
Consultant or advisor for: Adaptive; Artiva; AstraZeneca; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen; Pfizer; Regeneron; Sanofi
Speaker or member of speakers bureau for: Amgen; Bristol Myers Squibb Company; GlaxoSmithKline; Takeda
Research funding from: Janssen
Ownership interest: Bristol Myers Squibb Company
Other: Scientific advisory board for: SUTRO

Krina Patel, MD, MSc

Associate Professor
Center Medical Director
Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Krina Patel, MD, MSc, has the following relevant financial relationships:
Consultant or advisor for: ArcellX; Bristol Myers Squibb Company; Celgene; Cellectis; Janssen; Karyopharm; Oncopeptides; Pfizer
Contracted researcher for: Allogene; Bristol Myers Squibb Company; Celgene; Cellectis; Nektar; Precision; Takeda

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Lonial and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Lonial’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Sagar Lonial, MD, FACP, has the following relevant financial relationships:
Consultant or advisor for: Amgen; Bristol Myers Squibb Company; Celgene; Cellectis; GlaxoSmithKline; Janssen; Novartis; Takeda
Research funding from: CR Therapeutics; Janssen; Novartis; Takeda
Owns stock (publicly traded) in: TG Therapeutics
Other: Board of directors for: TG Therapeutics

Anita D'Souza, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosures

Anita D'Souza, MD, has the following relevant financial relationships:
Consultant or advisor for: Arivan; Bristol Myers Squibb Company; Eradigm; Janssen; Prothena
Research funding from: AbbVie; Caelum; Janssen; Novartis; Prothena; Regeneron; Sanofi; TeneoBio

Charise Gleason, MSN, NP-C, AOCNP

Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Advanced Practice Provider Chief
Winship Cancer Institute of Emory University
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Gleason and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Gleason’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Charise Gleason, MSN, NP-C, AOCNP, has no relevant financial relationships.

Kathryn Maples, PharmD, BCOP

Clinical Pharmacy Specialist
Emory Healthcare
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Maples and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Maples’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Kathryn Maples, PharmD, BCOP, has the following relevant financial relationships:
Consultant or advisor for: GlaxoSmithKline; Janssen; Sanofi

Editor

Megan Whitney, DMD

Medical Education Director, Medscape, LLC

Disclosures

Megan Whitney, DMD, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 2.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 2.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.25 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 2.50 contact hour(s) (0.250 CEUs) (Universal Activity Number: JA0007105-0000-22-360-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Multiple Myeloma

Authors: Session chair: Shaji Kumar, MD; Faculty: Anita D'Souza, MD; Charise Gleason, MSN, NP-C, AOCNP; Nisha Joseph, MD; Amrita Krishnan, MD, FACP; Sagar Lonial, MD, FACP; Kathryn Maples, PharmD, BCOP; Ajay Nooka, MD, MPH, FACP; Krina Patel, MD, MScFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/11/2022

Valid for credit through: 10/11/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

The Smoldering Myeloma Debate: To Treat or Not to Treat

Would you observe or treat a patient with smoldering myeloma? What is the rationale for each approach?
Shaji Kumar, MD; Nisha Joseph, MD

Advances in the Treatment of Newly Diagnosed Multiple Myeloma

Are there new treatment approaches for patients with newly diagnosed multiple myeloma?
Ajay Nooka, MD, MPH, FACP

Approaches to Maintenance Therapy in Multiple Myeloma

What is the latest data in maintenance therapy?
Amrita Krishnan, MD, FACP

Keys to Response Assessment in Multiple Myeloma

What is the role of response assessment in managing a patient with multiple myeloma?
Shaji Kumar, MD

Management of Early Relapsed/Refractory Multiple Myeloma

What are the latest advances in treatment for early relapsed/refractory multiple myeloma?
Sagar Lonial, MD, FACP

Evolving Treatment Strategies in Late Relapsed/Refractory Multiple Myeloma

How do you choose among the many treatment options for late relapsed/refractory multiple myeloma?
Krina Patel, MD, MSc

Supportive Care Considerations for Patients With Multiple Myeloma

How do you manage symptom burden and help improve quality of life in patients with multiple myeloma?
Anita D'Souza, MD

Interprofessional Myeloma Management: A Case-Based Discussion

Watch experts across the professions discuss the team approach to caring for patients with multiple myeloma.
Shaji Kumar, MD; Charise Gleason, MSN, NP-C, AOCNP; Kathryn Maples, PharmD, BCOP

Educational Impact Challenge

The goal of this activity is that learners will be better able to personalize treatment for patients with multiple myeloma in an interprofessional team-based environment by integrating clinical trial data and evidence-based recommendations on novel therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 11

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Session chair

Shaji Kumar, MD

Faculty

Nisha Joseph, MD

Ajay Nooka, MD, MPH, FACP

Amrita Krishnan, MD, FACP

Krina Patel, MD, MSc

Sagar Lonial, MD, FACP

Anita D'Souza, MD

Charise Gleason, MSN, NP-C, AOCNP

Kathryn Maples, PharmD, BCOP

Editor

Megan Whitney, DMD

Compliance Reviewer

Yaisanet Oyola, MD

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer:

CME / ABIM MOC / CE

Multiple Myeloma

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Session chair

Shaji Kumar, MD

Faculty

Nisha Joseph, MD

Ajay Nooka, MD, MPH, FACP

Amrita Krishnan, MD, FACP

Krina Patel, MD, MSc

Sagar Lonial, MD, FACP

Anita D'Souza, MD

Charise Gleason, MSN, NP-C, AOCNP

Kathryn Maples, PharmD, BCOP

Editor

Megan Whitney, DMD

Compliance Reviewer

Yaisanet Oyola, MD

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer:

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Multiple Myeloma

Contents of This CME Activity

The Smoldering Myeloma Debate: To Treat or Not to Treat

Advances in the Treatment of Newly Diagnosed Multiple Myeloma

Approaches to Maintenance Therapy in Multiple Myeloma

Keys to Response Assessment in Multiple Myeloma

Management of Early Relapsed/Refractory Multiple Myeloma

Evolving Treatment Strategies in Late Relapsed/Refractory Multiple Myeloma

Supportive Care Considerations for Patients With Multiple Myeloma

Interprofessional Myeloma Management: A Case-Based Discussion

Educational Impact Challenge